Status:

Do Not Prescribe (DNP), Red

Decision Date:

March 2023

Comments

RED: Treatment of aggressive and symptomatic rearranged during transfection (RET) mutant medullary thyroid cancer in patients aged ≥5 years with unresectable locally advanced or metastatic disease. NHSE commissioned.

DNP: NICE TA550 - Vandetanib for treating medullary thyroid cancer (January 2019)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again